ABSTRACT BACKGROUND Transcatheter aortic valve replacement (TAVR) is now the standard of care for patients with symp-
METHODS
TRIAL OVERSIGHT. The LRT trial (NCT02628899) was a prospective multicenter feasibility trial to test the safety of transfemoral TAVR in low-risk patients with symptomatic severe aortic stenosis (12) . The trial was an investigator-initiated study and was fully funded and managed by the sponsor (MedStar Health
Research Institute, Washington, DC) (Online Table 1 ).
Enrolling centers assumed the cost of all local research activities as well as the research-driven tests. The research protocol was approved by the relevant institutional review boards. All patients gave written informed consent and were evaluated before enrollment by an independent clinical review committee, comprising 1 interventional cardiologist and 1 cardiothoracic surgeon, to ensure low-risk status as well as clinical and anatomical eligibility for transfemoral TAVR. All echocardiographic and computed tomography (CT) imaging studies were analyzed by an independent core laboratory. The primary endpoint of the study was all-cause mortality at 30 days. A composite secondary endpoint of all-cause mortality, stroke, and >mild paravalvular aortic regurgitation was evaluated after adjustment. Secondary endpoints also included individual components of this composite and additional relevant procedural complications (12) . All clinical endpoints were adjudicated by an independent clinical events adjudication committee comprising an interventional cardiologist, a cardiothoracic surgeon, and a neurologist using both Valve Academic Research Consortium (VARC 2) and STS definitions (13) . The data were fully and independently monitored.
TAVR PATIENT SELECTION. Between February 16, 2016, and February 8, 2018 , 290 patients with symptomatic severe aortic stenosis were screened by the enrolling centers' multidisciplinary heart teams, and a total of 200 patients (Online Table 2 ) were confirmed to be low risk based on an STS-PROM score #3% and absence of comorbidity that would increase surgical risk, including, but not limited to, frailty, porcelain aorta, severe pulmonary hypertension, and advanced liver disease. Severe aortic Waksman et al. A complete list of trial inclusion and exclusion criteria is included in Online Table 3 . Table 4 .
CARDIAC CT ANALYSIS FOR LEAFLET THROMBOSIS.
CT scans were performed using 64-slice or greater multidetector row CT and contrast-enhanced retrospective electrocardiogram-gated acquisitions without dose modulation. Tube potential was set at 120 kV. Images were reconstructed at 10% intervals.
Images were reconstructed with <1.0-mm slice thickness and 50% slice overlap. Dedicated 3-dimensional analysis software (Synapse 3D, Fujifilm Medical Systems, Stamford, Connecticut) was used to create 2-dimensional axial and multiplanar reconstruction in valve specific planes. Images were evaluated in systole and diastole for structural abnormalities and leaflet motion. Abnormalities were defined using previously described criteria (14) .
Hypoattenuated leaflet thickening (HALT) was
defined as an area of CT hypoattenuation beginning at the leaflet insertion to the valve frame. Reduction in leaflet motion (RELM) was defined as mild (<50% Abbreviations as in Table 1 . CI ¼ confidence interval; MI ¼ myocardial infarction; all other abbreviations as in Table 1 . Table 2 ). The rate of vascular and bleeding complications was low (Table 3) . 
DISCUSSION
The LRT trial is the first U.S. TAVR trial in low-risk patients with symptomatic severe aortic stenosis.
The key findings can be summarized as follows: TAVR in low-risk patients was safe, with zero mortality and zero disabling stroke at 30 days (Central Illustration). Four-dimensional (4D) contrast-enhanced CT or TEE was performed in TAVR patients at 30-day follow-up. TAVR leaflet findings were defined according to Jilaihawi et al. (14) .
All imaging studies were analyzed in an independent core lab. CT ¼ computed tomography; TAVR ¼ transcatheter aortic valve replacement; TEE ¼ transesophageal echocardiography.
TAVR in Low-Risk Patients
The finding of zero mortality and zero disabling contrast, the expected mortality in the TAVR cohort was 1.8% and the observed 30-day mortality rate was 0%. Thus, STS-PROM appeared to overestimate mortality in TAVR patients, which is consistent with prior observations (15) .
The greatest mortality benefit for TAVR over SAVR is in high-risk patients (3, 4) . In low-risk patients, there may not be a significant mortality benefit.
Rather the benefit may be in shorter hospital length of stay, swifter recovery, and superior prosthesis he- 
